Vir Biotechnology, Inc. VIR Business Segments — Clinical costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept vir:ResearchAndDevelopmentClinicalCosts.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s business segments — clinical costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s business segments — clinical costs?
- Vir Biotechnology, Inc. (VIR) reported business segments — clinical costs of $26.13M in Q1 2026.
- How has Vir Biotechnology, Inc.'s business segments — clinical costs changed year-over-year?
- Vir Biotechnology, Inc.'s business segments — clinical costs increased by 26.8% year-over-year, from $20.61M to $26.13M.
- What is the long-term trend for Vir Biotechnology, Inc.'s business segments — clinical costs?
- Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s business segments — clinical costs has grown at a -9.8% compound annual growth rate (CAGR), from $118.85M to $87.17M.
- What does business segments — clinical costs mean?
- Includes all direct expenditures related to conducting clinical trials, such as patient recruitment, site management, and data analysis for drug candidates. It is a critical measure of the investment intensity required to advance the company's pipeline through regulatory approval stages.